The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and Parkinson’s disease, has increased as the population has aged. At the same time, technological developments, such as brain mapping, have improved.
Private equity firms are investing in a wide range of companies involved in treatments, including drug development, infusion services and medical devices.
